$ADI

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More

Wall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include Analog Devices (ADI) to Outperform at Bernstein, Etsy (ETSY) to Buy at Bank of America, and Merck & Co (MRK) to Overweight at Morgan Stanley. Downgrades include Allstate (ALL) to Underperform at Keefe Bruyette and TJX Companies (TJX) to Neutral at Citigroup. Initiations include Alphabet (GOOGL) and Shopify (SHOP) with Buy ratings at Rosenblatt.

Original reporting
Published Aug 20, 2026, 12:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More — source image
Decision brief

The 30-second read

$ADIBullishLow
01

Why it matters

Aggregated analyst actions provide modest directional cues but lack a single material catalyst.

02

Market read

The list of rating changes offers incremental insight for traders monitoring analyst sentiment.

03

What to watch

Macro backdrop of Treasury bond buyback could affect risk appetite.

Relevance 4/10Novelty 2/10Timing: today

Background

Daily analyst coverage roundup highlighting upgrades, downgrades, and initiations across multiple sectors.

Company-level read

Ticker impact

$ADIBullishMedium confidence
Context

Analog Devices upgraded to Outperform with a $465 price target.

Expected impact

Small upside over next weeks.

Evidence & confidence

Upgrade signals improved earnings expectations.

$CCINeutralMedium confidence
Context

Crown Castle upgraded to Overweight with target trimmed to $85.

Expected impact

Limited price movement.

Evidence & confidence

Overweight rating but lower target suggests caution.

$ETSYBullishMedium confidence
Context

Etsy upgraded to Buy with $105 target.

Expected impact

Potential short‑term rally.

Evidence & confidence

Analyst confidence may attract buyers.

$EPRBullishMedium confidence
Context

EPR Properties raised to Overweight with $70 target.

Expected impact

Modest upside.

Evidence & confidence

Higher rating suggests better income prospects.

$MRKBullishMedium confidence
Context

Merck upgraded to Overweight with target raised to $179.

Expected impact

Potential upside over months.

Evidence & confidence

Overweight rating reflects strong pipeline.

$ALLBearishMedium confidence
Context

Allstate downgraded to Underperform with target $250.

Expected impact

Possible short‑term decline.

Evidence & confidence

Lower rating signals weaker outlook.

$WHDNeutralMedium confidence
Context

Cactus downgraded to Neutral with $75 target.

Expected impact

Sideways range.

Evidence & confidence

Downgrade reflects concerns.

$COTYBearishMedium confidence
Context

Coty cut to Sector Perform with target $3.

Expected impact

Downward pressure.

Evidence & confidence

Target cut reflects weak performance.

Market effects

Broad analyst upgrades may lift sector sentiment modestly.

US equity markets see slight positive bias from coverage.

Limited; primarily US-listed equities.

Counterpoint

Upgrades may be premature if earnings miss expectations later.

Key entities

  • Bernstein

    Upgraded Analog Devices.

  • Barclays

    Upgraded Crown Castle.

Related articles

$MRKMedAI 8/10

Why Are Merck Shares Hitting All

Merck (MRK) shares fell 1.38% after a 12.6% gain, reaching $150.10. The company and Moderna reported positive Phase 3 trial results for a cancer vaccine combined with Keytruda, meeting primary and secondary endpoints. Keytruda sales were $8.4B in Q2, up 4% YoY. Merck's R&D spending led to a $5.6B net loss in H1 2026, but operating cash flow doubled to $9.3B. Analysts note the stock is 8% above average targets.

$MRKHighAI 9/10

mRNA Cancer Vaccine Wins Melanoma Trial: Merck-Moderna Breakthrough Explained

Merck and Moderna reported that their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and metastasis in a Phase 3 trial. The study met its primary and secondary endpoints, leading to an early stop. Detailed results will be presented later. The companies did not disclose hazard ratios. Shares of both companies reportedly surged following the announcement.

$MRNAHighAI 8/10

Finding the next Moderna: 5 biotech stocks with imminent FDA and trial catalysts

Moderna (MRNA) shares fell 7.7% premarket after a 177% surge following positive trial results for its mRNA cancer vaccine. Five biotech stocks with imminent FDA catalysts are highlighted: Regeneron (REGN), Ultragenyx (RARE), Alnylam (ALNY), Merck (MRK), and Ionis (IONS). Each has recent approvals, upcoming data presentations, or earnings events that could impact their stock prices. Financial metrics and analyst targets are provided for each company. Bitcoin hit $72k after Trump's crypto legislat

$CCIMed

Crown Castle Draws an Upgrade With a Lower Price Target

Crown Castle (CCI) gained 0.47% premarket after Barclays upgraded it to Overweight, cutting its price target to $84 from $92. Barclays believes CCI is not overly exposed to satellite competition and expects core leasing to accelerate. The firm argues CCI should trade above peers due to strong US tower market performance and a 5.7% dividend yield.